E126: Risk Signals, JAKs, and SELECTIVE-ity
From The Evidence Based Rheumatology Podcast by Michael Putman
September 8, 2025 · 15 min · Episode 127
About this episode
The episode discusses a post hoc study of upadacitinib trials in rheumatoid arthritis, exploring the implications of JAK inhibitors.
Covering an interesting but ultimately disappointing post hoc study of multiple upadacitinib trials in RA. Initially some hope for clarity in the "Do JAKs cause all the badness?" questions, but ultimately landing me about where I have been since ORAL-SURVEILLANCE was published Paper: https://www.sciencedirect.com/science/article/pii/S0003496724423091
People in this episode
Host: Michael Putman
Topics covered
- rheumatology
- JAK inhibitors
- upadacitinib
- RA
- clinical trials
- post hoc study
Keywords
- rheumatoid arthritis
- JAKs
- upadacitinib
- clinical trials
- post hoc analysis
- ORAL-SURVEILLANCE
- risk signals
Mentioned in this episode
Organizations: ScienceDirect
Books & works: ORAL-SURVEILLANCE, upadacitinib
More episodes of The Evidence Based Rheumatology Podcast
- E135: IL17 and a GLP1? · April 30, 2026 · 11 min
- E134: Brepocitinib in Dermatomyositis (VALOR) · April 17, 2026 · 15 min
- E133: Obinutuzumab for SLE (ALLEGORY) · March 19, 2026 · 15 min
- E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE) · March 5, 2026 · 14 min
- E131: A Sham-Controlled Sham of a Trial: RESET-RA · January 21, 2026 · 15 min
- E130: Telitacicept for SLE · December 22, 2025 · 13 min
Explore listener stats, chart rankings, contacts and more on the The Evidence Based Rheumatology Podcast podcast page.